Summary
15.65 -0.01(-0.03%)09/27/2024
NovoCure Ltd (NVCR)
NovoCure Ltd (NVCR)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.19 | -10.14 | -12.38 | -11.88 | 7.08 | -7.97 | -78.70 | -14.41 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 15.65 | |
| Open | 16.01 | |
| High | 16.16 | |
| Low | 15.46 | |
| Volume | 453,358 | |
| Change | 0.03 | |
| Change % | 0.19 | |
| Avg Volume (20 Days) | 492,191 | |
| Volume/Avg Volume (20 Days) Ratio | 0.92 | |
| 52 Week Range | 10.87 - 24.74 | |
| Price vs 52 Week High | -36.76% | |
| Price vs 52 Week Low | 43.93% | |
| Range | -2.28 | |
| Gap Up/Down | -0.24 | |
Fundamentals | ||
| Market Capitalization (Mln) | 1,694 | |
| EBIDTA | 225,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | -0.4700 | |
| WallStreet Target Price | 119.33 | |
| Book Value | 3.9800 | |
| Earnings Per Share | -0.2680 | |
| EPS Estimate Current Quarter | -0.0700 | |
| EPS Estimate Next Quarter | -0.0600 | |
| EPS Estimate Current Year | -0.4100 | |
| EPS Estimate Next Year | -0.3600 | |
| Diluted EPS (TTM) | -0.2680 | |
| Revenues | ||
| Profit Marging | -0.0494 | |
| Operating Marging (TTM) | -0.0155 | |
| Return on asset (TTM) | -0.0068 | |
| Return on equity (TTM) | -0.0749 | |
| Revenue TTM | 545,771,008 | |
| Revenue per share TTM | 5.3020 | |
| Quarterly Revenue Growth (YOY) | 0.0070 | |
| Quarterly Earnings Growth (YOY) | -0.0600 | |
| Gross Profit (TTM) | 388,274,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 588.2353 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 21.1702 | |
| Revenue Enterprise Value | 15.3652 | |
| EBITDA Enterprise Value | 4,066.8542 | |
| Shares | ||
| Shares Outstanding | 103,819,000 | |
| Shares Float | 88,831,909 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 13.35 | |
| Institutions (%) | 75.88 | |
09/09 07:00 EST - businesswire.com
Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure to Present Real-World Data at ESMO 2024.
Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure to Present Real-World Data at ESMO 2024.
09/06 17:19 EST - fool.com
Why NovoCure Stock Dived by 13% This Week
The commercial-stage biotech's leader is stepping down. This change is effective on Jan. 1, 2025.
Why NovoCure Stock Dived by 13% This Week
The commercial-stage biotech's leader is stepping down. This change is effective on Jan. 1, 2025.
08/16 11:01 EST - zacks.com
Wall Street Analysts Think NovoCure (NVCR) Could Surge 35.96%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 36% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Think NovoCure (NVCR) Could Surge 35.96%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 36% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
08/01 08:21 EST - zacks.com
New Strong Buy Stocks for August 1st
NVCR, KGC, CVNA, KNSA and MU have been added to the Zacks Rank #1 (Strong Buy) List on August 1, 2024.
New Strong Buy Stocks for August 1st
NVCR, KGC, CVNA, KNSA and MU have been added to the Zacks Rank #1 (Strong Buy) List on August 1, 2024.
07/30 10:56 EST - zacks.com
Wall Street Analysts Believe NovoCure (NVCR) Could Rally 26.39%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 26.4% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Believe NovoCure (NVCR) Could Rally 26.39%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 26.4% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
07/26 12:34 EST - seekingalpha.com
NovoCure Limited: A Post Q2 Analysis
Today, we take a look at NovoCure Limited, which develops and manufactures tumor treating fields devices for solid tumor cancers. The company has beat expectations for both its first and second quarter results in 2024 and is pushing to garner approval for additional indications. An analysis of NovoCure following its better than expected performance Q2 results Thursday follows in the paragraphs below.
NovoCure Limited: A Post Q2 Analysis
Today, we take a look at NovoCure Limited, which develops and manufactures tumor treating fields devices for solid tumor cancers. The company has beat expectations for both its first and second quarter results in 2024 and is pushing to garner approval for additional indications. An analysis of NovoCure following its better than expected performance Q2 results Thursday follows in the paragraphs below.
07/25 12:35 EST - seekingalpha.com
NovoCure Limited (NVCR) Q2 2024 Earnings Call Transcript
NovoCure Limited [NVCR] Q2 2024 Earnings Conference Call July 25, 2024 8:00 AM ET Company Participants Bill Doyle - Executive Chairman Asaf Danziger - CEO Ashley Cordova - CFO Frank Leonard - EVP and President of NovoCure Oncology Nicolas Leupin - Chief Medical Officer Ingrid Goldberg - Investor Relations Conference Call Participants Jonathan Chang - Leerink Partners Jason Bednar - Piper Sandler Larry Biegelsen - Wells Fargo Jessica Fye - J.P. Morgan Vijay Kumar - Evercore ISI Emily Bodnar - H.C.
NovoCure Limited (NVCR) Q2 2024 Earnings Call Transcript
NovoCure Limited [NVCR] Q2 2024 Earnings Conference Call July 25, 2024 8:00 AM ET Company Participants Bill Doyle - Executive Chairman Asaf Danziger - CEO Ashley Cordova - CFO Frank Leonard - EVP and President of NovoCure Oncology Nicolas Leupin - Chief Medical Officer Ingrid Goldberg - Investor Relations Conference Call Participants Jonathan Chang - Leerink Partners Jason Bednar - Piper Sandler Larry Biegelsen - Wells Fargo Jessica Fye - J.P. Morgan Vijay Kumar - Evercore ISI Emily Bodnar - H.C.
07/25 09:10 EST - zacks.com
NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates
NovoCure (NVCR) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.54 per share a year ago.
NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates
NovoCure (NVCR) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.54 per share a year ago.
06/03 08:00 EST - businesswire.com
METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today announced the presentation of clinical data from the phase 3 METIS trial, which investigated the use of Tumor Treating Fields (TTFields) therapy in the treatment of brain metastases from non-small cell lung cancer (NSCLC). These data will be presented at the ongoing 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The METIS trial enrolled 298 adult patients with 1-10 brain metastases from NSCLC, who we.
METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today announced the presentation of clinical data from the phase 3 METIS trial, which investigated the use of Tumor Treating Fields (TTFields) therapy in the treatment of brain metastases from non-small cell lung cancer (NSCLC). These data will be presented at the ongoing 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The METIS trial enrolled 298 adult patients with 1-10 brain metastases from NSCLC, who we.
05/23 17:05 EST - businesswire.com
TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today released topline efficacy and safety data from the TIGER study investigating the use of Tumor Treating Fields (TTFields) therapy in routine clinical care in the treatment of patients with newly diagnosed glioblastoma (GBM) in Germany. The TIGER study enrolled 429 patients who used TTFields therapy between August 2017 and November 2019 and is the largest prospective, non-interventional study of the use of TTFields therapy in routi.
TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today released topline efficacy and safety data from the TIGER study investigating the use of Tumor Treating Fields (TTFields) therapy in routine clinical care in the treatment of patients with newly diagnosed glioblastoma (GBM) in Germany. The TIGER study enrolled 429 patients who used TTFields therapy between August 2017 and November 2019 and is the largest prospective, non-interventional study of the use of TTFields therapy in routi.
05/14 07:08 EST - investorplace.com
Double-Up Delights: 7 Stocks Poised to Soar 100% by 2025
If you're wondering what stocks to buy this month, look no further. Every investor wants their stock picks to double in price.
Double-Up Delights: 7 Stocks Poised to Soar 100% by 2025
If you're wondering what stocks to buy this month, look no further. Every investor wants their stock picks to double in price.
05/02 09:31 EST - zacks.com
NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates
NovoCure (NVCR) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.50 per share a year ago.
NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates
NovoCure (NVCR) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.50 per share a year ago.
05/02 07:01 EST - businesswire.com
Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) announced today that it has entered into a new five-year up to $400 million committed senior secured credit facility with funds managed by Pharmakon Advisors, LP. The committed capital will be available to Novocure in four tranches of $100 million. The first $100 million was issued at closing, and the second $100 million will be issued by June 30, 2025. An additional $200 million is available to be drawn across two tranches, at Novocur.
Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) announced today that it has entered into a new five-year up to $400 million committed senior secured credit facility with funds managed by Pharmakon Advisors, LP. The committed capital will be available to Novocure in four tranches of $100 million. The first $100 million was issued at closing, and the second $100 million will be issued by June 30, 2025. An additional $200 million is available to be drawn across two tranches, at Novocur.
05/02 07:00 EST - businesswire.com
Novocure Reports First Quarter 2024 Financial Results
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2024. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). “The first quarter was a period of strong execution,” said William Doyle, Novocure's Executive Chairman. “In Q1, GBM active patients grew 11%, we announced the METI.
Novocure Reports First Quarter 2024 Financial Results
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2024. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). “The first quarter was a period of strong execution,” said William Doyle, Novocure's Executive Chairman. “In Q1, GBM active patients grew 11%, we announced the METI.
04/25 11:07 EST - zacks.com
NovoCure (NVCR) Expected to Beat Earnings Estimates: Should You Buy?
NovoCure (NVCR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NovoCure (NVCR) Expected to Beat Earnings Estimates: Should You Buy?
NovoCure (NVCR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
04/24 10:45 EST - businesswire.com
Results of Novocure's METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today announced the results of the METIS phase 3 clinical trial in brain metastases from non-small cell lung cancer (NSCLC) will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, to be held from May 31 to June 4. METIS was a randomized phase 3 clinical trial of stereotactic radiosurgery with or without Tumor Treating Fields (TTFields) therapy for patients with 1-10 brain metastases from NS.
Results of Novocure's METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today announced the results of the METIS phase 3 clinical trial in brain metastases from non-small cell lung cancer (NSCLC) will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, to be held from May 31 to June 4. METIS was a randomized phase 3 clinical trial of stereotactic radiosurgery with or without Tumor Treating Fields (TTFields) therapy for patients with 1-10 brain metastases from NS.
04/05 07:00 EST - businesswire.com
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today announced 20 presentations on Tumor Treating Fields (TTFields) therapy will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2024, to be held April 5 to 10 in San Diego. The presentations, describing preclinical investigations, include new insights on how TTFields therapy can potentially enhance the immune system's ability to combat cancer cells and on TTFields therapy's effects and mechanisms in.
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today announced 20 presentations on Tumor Treating Fields (TTFields) therapy will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2024, to be held April 5 to 10 in San Diego. The presentations, describing preclinical investigations, include new insights on how TTFields therapy can potentially enhance the immune system's ability to combat cancer cells and on TTFields therapy's effects and mechanisms in.
04/01 13:00 EST - zacks.com
NovoCure (NVCR) Moves to Buy: Rationale Behind the Upgrade
NovoCure (NVCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
NovoCure (NVCR) Moves to Buy: Rationale Behind the Upgrade
NovoCure (NVCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
03/30 06:34 EST - fool.com
Why NovoCure Stock Soared 18.3% This Week
Novocure announced encouraging results from a phase 3 study of its TTFields therapy in treating brain metastases. The therapy previously failed to reach a primary endpoint in a separate study for treating platinum-resistant ovarian cancer.
Why NovoCure Stock Soared 18.3% This Week
Novocure announced encouraging results from a phase 3 study of its TTFields therapy in treating brain metastases. The therapy previously failed to reach a primary endpoint in a separate study for treating platinum-resistant ovarian cancer.
03/28 11:50 EST - fool.com
Why Novocure Stock Is Jumping Today
Novocure announced results from a phase 3 study of its TTFields therapy in treating brain metastases. Patients treated with TTFields experienced a significant improvement in the median time to intracranial progression.
Why Novocure Stock Is Jumping Today
Novocure announced results from a phase 3 study of its TTFields therapy in treating brain metastases. Patients treated with TTFields experienced a significant improvement in the median time to intracranial progression.